Newsfeed : Drug Trade Groups Want Patients to Oppose Full Trial Data

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Newsfeed » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 6, 2013

Drug Trade Groups Want Patients to Oppose Full Trial Data

Two drug trade groups sent a memo to senior industry executives proposing to get patient groups “to express concern about the risk to public health by nonscientific reuse of data,” The Guardian reports. The U.K. newspaper claims a drug company employee leaked the memo.

The European Medicines Agency (EMA) is considering mandating full disclosure of data from clinical trials. Currently, about half of the data is published from such trials. Proponents of full data disclosure believe such transparency would help scientists and patients. The Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) oppose such intervention by the EMA.

As a result, PhRMA and EFPIA created a four-part strategy to sow doubts, and the memo details their plan. In addition to enlisting patient groups to raise concerns, the strategy seeks to enlist scientific groups and business groups. The strategy also calls for a network of academics to correct false interpretations of data. The memo was sent to directors and legal counsel at Roche, Merck, Pfizer, GSK, AstraZeneca, Eli Lilly, Novartis and others.

In response, the Treatment Action Group (TAG) and a coalition of HIV/AIDS advocacy groups and individual advocates are urging patient groups and other stakeholders worldwide to support full data disclosure, according to a TAG statement. In particular, the coalition urges support of the AllTrials Initiative, a petition seeking such disclosure.

To read the article, click here.

To read the statement, click here.

To sign the petition, click here.

Search: clinical, trial, data, EMA, PhRMA, EFPIA, TAG, AllTrials

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.